&w=3840&q=100)
Indian pharma eyes US gains as $63.7 bn patent cliff nears: Analysts
This shift is expected to spur a rise in generic launches, particularly benefiting Indian players with emerging US operations and expertise in complex generics.
Firms such as Alembic Pharmaceuticals and Shilpa Medicare, which have smaller US footprints, and larger players like Cipla and Lupin, which have invested early in differentiated products such as injectables and respiratory therapies, are seen as well positioned to gain market share. With global majors like Teva, Viatris and Sandoz having closed dozens of manufacturing sites since 2018, Indian companies are stepping in to fill the supply gap.
However, the opportunity is unfolding amid growing strategic discipline. Filings of Abbreviated New Drug Applications (ANDAs) in the US declined 25 per cent year-on-year. FY25 filings are projected to close around 550—down from 740 in FY24 and 857 in FY22. This signals a pivot from volume to portfolio quality, regulatory compliance and margin protection.
Commenting on this shift, Nilaya Varma, Group CEO and Co-founder of Primus Partners, said, 'India's pharma exports have grown from $15 billion in 2013–14 to nearly $28 billion in a decade. With 750+ USFDA-approved plants and rising strength in complex generics and biosimilars, India is primed to lead the next wave of affordable, high-quality medicines. Tapping the $180 billion LoE opportunity will require continued focus on compliance and quality systems.'
Regulatory headwinds are also easing. The share of US FDA inspections resulting in Official Action Indicated (OAI) for Indian firms has fallen from 19 per cent in 2013 to 9 per cent in 2023. Companies like Cipla are further de-risking their US supply chains by adopting multi-site manufacturing and digital quality systems.
Cipla, which holds a robust US portfolio of 284 ANDA and NDA filings—175 of which are approved and 73 under review—is focusing on commercialisation-ready products, including PEPFAR-approved generics. The company is betting on complex respiratory and injectable therapies to drive growth.
Pharma major Lupin, which continues to benefit globally from its blockbuster autoimmune biologic Etanercept, plans to finalise its US commercialisation strategy closer to the drug's 2029 patent expiry.
Meanwhile, Sun Pharma, despite offering a conservative FY26 outlook amid global macro uncertainties, is expanding its oncology pipeline. Its recently acquired UNLOXCYT (cosibelimab) is expected to significantly contribute to US revenues. The company noted that Keytruda's upcoming patent expiry was already factored into the acquisition. UNLOXCYT targets only one of Keytruda's multiple indications, and Sun remains confident in its potential to become a meaningful contributor to its US specialty business.
In parallel, Sun is also strengthening its immunotherapy portfolio through a global licensing agreement with Philogen.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Deccan Herald
an hour ago
- Deccan Herald
The rhetoric and real costs of trade wars
India misread the tariffs brought on by the United States and, at a broader level, the Trump administration. We were one of the first to approach the US on this matter, and we continued to believe that we would have a favourable deal till recently, given what we felt was a great rapport between Modi and Trump. Mainstream electronic media houses were complicit in driving this narrative. To understand why India got it wrong, it would be useful to connect two disparate data dots. Top that with India's misreading of Trump's desire to be seen as a look at the first irritant and its impact. India exports roughly $90 billion, paying approximately 2 per cent tariffs currently, and imports roughly $45 billion at 12 per cent tariffs. The trade deficit of $45 billion carries a tariff differential of $5 billion per year in India's favour after adjusting for exempted products. We should have seen this imbalance in America's trade deficit and tariffs long ago and proactively addressed this. Modi is now overhauling the tax rates in a bid to boost the economy. This is expected to cost $20 billion, four times the tariff differential India was enjoying. .The other irritant is oil imports. In 2021/22, India imported roughly 2.5 million barrels of oil every day. Under the tacit approval of the West, India's imports from Russia grew from 2 per cent then to 40 per cent today. India buys 45 per cent of the exported oil from Russia, a growth of 1900 per cent from pre-war levels. China buys the same percentage, a growth of 50 per cent from pre-war levels. So why did India need this extra oil suddenly? It was because we processed this extra oil and sold it for a profit overseas. Therefore, the rhetoric is misplaced, as we are profiting and fuelling the Russian war machine. Predicting the flow of events, we should have scaled down our offtake back to the 2022 levels and with that, justify our need to fuel the Indian economy and keep inflationary tendencies in check. We have now started to do this, drawing a balance between the US and predict that the impact of tariffs at 25 per cent is likely to be in the region of $11-12 billion per annum on tariffed goods and about 0.25 per cent on GDP. In the earliest days of cranking up our imports of oil, the difference was around $30 a barrel, leading to a gain of $16 billion. That has now come down to around $5 a barrel after accounting for logistics, etc. The benefit we get is estimated today to be only $3.5 billion, a delta of $8.5 billion from what we lose out on with the long commentators have suggested many responses, ranging from the knee-jerk to keeping the long-term in mind. The real issue is what we do now. There is no pattern in the madness. Why have the four treatments of the BRIC countries been different? Because there is a different playbook with each one. With Brazil, the US has a trade surplus. Why then, do they have tariffs of 50 per cent, which is higher than China and equal to India? Bolsonaro? With China, 150 per cent was brought down to 30 per cent; here, it is about the rare earths. For the quantities required, the ecosystem is expensive, and the returns don't work out for a commercial operation. The CCP subsidised this for leverage and their long-term plans to pursue electric mobility and clean energy. This leverage on supplies was used to resolve the $650 billion of trade at stake between the US and China. .India made public its hypocritical treatment at the hands of the US, as it bought palladium, uranium, etc. from Russia. However, the reality is that US imports from Russia were at best $3 billion, down some 45 per cent from the previous year. India's imports from Russia stood at $70 billion, almost twice what it imports from the must now not get caught in the whirlpool of its rhetoric. And it certainly must not seek to appease China and Russia in a hurry and on the rebound. One can expect that this is short-term. There are many moving parts – Russia and Ukraine could arrive at a truce as early as next month. India has already started to demonstrate it is willing to reduce its import of Russian oil while not displeasing Russia. The midterms in the US could go against Trump, and the US courts could reverse Trump's executive decisions. Importantly, Trump does not define the long-standing US relationship with India. Trump himself may not have a long-term view on this the US, it seems clear. The average tariff on its imports has seen inflows of $28 billion, three times post these levies were collected in June. This aggregates to $350 billion. Add to this DOGE cuts and some others, and we have $500 billion being saved or added to the US treasury. This pays half its annual interest cost of $1 trillion, which, if left alone, is not sustainable. This is good for no one, as it is the world's biggest market by the short term, one sees no harm in subtly managing the relationships and dynamics at play and being practical. In the long term, anyway, as economist John Maynard Keynes said, we are all dead..(The writer is the former managing director of a Tata Company and now runs a Bengaluru-headquartered corporate finance practice)
NDTV
an hour ago
- NDTV
Want To Live In Portugal? Indians Can Apply For A Golden Visa But There's A Catch
Known for its beautiful coastline and rich history, Portugal has emerged as one of Europe's most attractive destinations for Indians seeking permanent residency (PR). With its unique culture and high quality of life, Portugal offers a Golden Visa that allows you to stay and live there. What Is Portugal's Golden Visa? The Portugal Golden Visa is a residency by investment program that allows you to live, work, and study in the country. It also gives visa-free access to the Schengen Area. It also opens up an oppotunity for Indian citizens a chance to secure residency in Portugal and eventually EU citizenship through qualifying investments. Who Is Eligible? You can apply for a Portugal Golden Visa if you meet the following requirements: Should be 18 years or older. Open to all non-EU/EEA/Swiss nationals, including Indians. A clean criminal record from Indian or any other country where they have lived recently. Someone who can either purchase a property, transfer capital, or invest in businesses or funds. Applicant must stay in the country for 7-14 days per year to maintain residency. The catch? You need to invest a hefty amount of funds to obtain Portugal's Golden Visa. There are different types of investments that you can do, including: A fund subscription, which basically includes a minimum of €500,000 subscription in a qualifying Portuguese fund, such as Venture Capital funds and Private Equity. Start a new business wherein you create 10 new full-time jobs in Portugal. Invest a minimum of €500,000 in an existing Portuguese business and create five full-time jobs for at least 3 years. Make a donation of €500,000 for a research and development activity in Portugal. You can also invest €250,000 in preserving national heritage in Portugal. Note: As per the latest update, the real estate investment is no longer an option after October 2023 for new applicants. Documents Required Completed the Golden Visa application form A valid passport issued within the last 10 years and with a validity of 3 months Passport-sized photographs Police clearance certificate Proof of investments Portuguese bank statement confirming the investment transfer A statement stating investment for 5 years A valid health insurance covering at least €30,000 in the Schengen states Tax and social security clearance from Portugal, issued within 45 days Proof of fee payment for the application and processing How To Apply Step 1: Get a Portugese Tax Number and a bank account for completing an investment. Step 2: Make the investment by transferring funds from outside Portugal and complete the qualifying investment. The investment must be maintained for at least 5 years. Step 3: All documents must be notarized, apostilled, and translated into Portuguese if necessary. Step 4: Submit the application online, which is filed through Potugal's official immigration portal (AIMA or Agencia para a Integracao, Migracoes e Asilo). Step 5: Once the application is approved, you must travel to Portugal to provide fingerprints and photos. Step 6: The initial residence permit is valid for 2 years, renewable for another 3 years, leading to permanent residency and citizenship after 5 years. As per the latest update, the Portuguese government proposed some changes to the nationality law that may change Golden Visa rules. However, the proposal is currently under review. It is recommended to keep following the official website for the latest updates.
Economic Times
an hour ago
- Economic Times
Retail fuel margins propel oil PSUs' Q1 net up 2.5-fold
Synopsis Indian Oil Corporation, Hindustan Petroleum, and Bharat Petroleum saw profits rise significantly in the June quarter. High retail margins on petrol and diesel fueled this growth. However, inventory losses impacted refining margins. Discounts on Russian crude are shrinking. Some refiners are delaying Russian oil orders due to potential US penalties. Government compensation for LPG under-recoveries may provide additional support. iStock Indian Oil Corporation, Hindustan Petroleum Corporation (HPCL) and Bharat Petroleum Corporation (BPCL) posted a combined profit of ₹16,184 crore in the quarter to June, an increase of more than two and a half times year-on-year, buoyed by extraordinary retail margins on petrol and diesel despite heavy inventory earned the state-run oil marketers an estimated ₹10.3 per litre at the pump, up from ₹ 4.4 a year earlier, while diesel fetched ₹8.2 per litre versus ₹2.5, according to brokerage ICICI Securities. These gains came from a domestic price freeze even as international fuel prices slid - crude down 21%, petrol 18% and diesel 16%, as per petroleum and natural gas ministry data. The sharp fall in crude, however, inflicted large inventory losses, eroding refining margins. Indian Oil Corporation alone booked an inventory loss of ₹6,465 crore in the June quarter against a gain of ₹3,345 crore in the year-ago period. Its gross refining margin (GRM) fell to $2.15 a barrel from $6.39. Adjusted for inventory swings, GRM improved to $6.91, compared with $2.84 last expect strong marketing margins to persist if crude prices remain soft and domestic pump rates stay unchanged. But refiners face headwinds as imports of discounted Russian oil become less certain and price discounts narrow, eroding the crude-cost advantage. Companies are also diversifying their crude basket to manage supply risks. Discounts on Russian crude have shrunk to $1.5-2 per barrel, according to industry executives. Some Indian refiners are delaying orders for September-loading Russian oil cargoes as they await clarity on how US President Donald Trump's proposed 25% oil purchase-linked penalty will play out. The penalty takes effect on August 27, and some refiners are unwilling to take chances. For refiners, additional earnings support in this quarter could come from the government's decision to release ₹30,000 crore to compensate oil companies for LPG under-recoveries.
